Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Osteosarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (668
)
Soft Tissue Sarcoma (443
)
Spindle Cell Sarcoma (100
)
Leiomyosarcoma (54
)
Ewing Sarcoma (45
)
Fibrosarcoma (34
)
Rhabdomyosarcoma (34
)
Liposarcoma (25
)
Uterine Corpus Leiomyosarcoma (23
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (13
)
Sarcoma (668
)
Soft Tissue Sarcoma (443
)
Spindle Cell Sarcoma (100
)
Leiomyosarcoma (54
)
Ewing Sarcoma (45
)
Fibrosarcoma (34
)
Rhabdomyosarcoma (34
)
Liposarcoma (25
)
Uterine Corpus Leiomyosarcoma (23
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (13
)
›
Associations
(54)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
methotrexate
Sensitive: A1 - Approval
methotrexate
Sensitive
:
A1
methotrexate
Sensitive: A1 - Approval
methotrexate
Sensitive
:
A1
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
gemcitabine + docetaxel + cyclophosphamide
Sensitive: A2 - Guideline
gemcitabine + docetaxel + cyclophosphamide
Sensitive
:
A2
gemcitabine + docetaxel + cyclophosphamide
Sensitive: A2 - Guideline
gemcitabine + docetaxel + cyclophosphamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide + etoposide IV
Sensitive
:
A2
carboplatin + cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide + etoposide IV
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide
Sensitive
:
A2
carboplatin + cyclophosphamide
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
gemcitabine + docetaxel + ifosfamide
Sensitive: A2 - Guideline
gemcitabine + docetaxel + ifosfamide
Sensitive
:
A2
gemcitabine + docetaxel + ifosfamide
Sensitive: A2 - Guideline
gemcitabine + docetaxel + ifosfamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + ifosfamide + etoposide IV
Sensitive
:
A2
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + ifosfamide + etoposide IV
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
carboplatin + ifosfamide
Sensitive: A2 - Guideline
carboplatin + ifosfamide
Sensitive
:
A2
carboplatin + ifosfamide
Sensitive: A2 - Guideline
carboplatin + ifosfamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
cisplatin + ifosfamide + pegylated liposomal doxorubicin
Sensitive
:
A2
cisplatin + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
cisplatin + ifosfamide + pegylated liposomal doxorubicin
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
ifosfamide + methotrexate + etoposide oral
Sensitive: A2 - Guideline
ifosfamide + methotrexate + etoposide oral
Sensitive
:
A2
ifosfamide + methotrexate + etoposide oral
Sensitive: A2 - Guideline
ifosfamide + methotrexate + etoposide oral
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
sorafenib + everolimus
Sensitive: A2 - Guideline
sorafenib + everolimus
Sensitive
:
A2
sorafenib + everolimus
Sensitive: A2 - Guideline
sorafenib + everolimus
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride
Sensitive
:
A2
TMB-H
Osteosarcoma
TMB-H
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Osteosarcoma
MSI-H/dMMR
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
MAP
Sensitive: A2 - Guideline
MAP
Sensitive
:
A2
MAP
Sensitive: A2 - Guideline
MAP
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
NTRK2 fusion
Osteosarcoma
NTRK2 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Osteosarcoma
NTRK1 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
NTRK3 fusion
Osteosarcoma
NTRK3 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
CDK4 overexpression
Osteosarcoma
CDK4 overexpression
Osteosarcoma
palbociclib
Sensitive: C2 – Inclusion Criteria
palbociclib
Sensitive
:
C2
palbociclib
Sensitive: C2 – Inclusion Criteria
palbociclib
Sensitive
:
C2
ERCC1 K504Q
Osteosarcoma
ERCC1 K504Q
Osteosarcoma
cisplatin
Resistant: C3 – Early Trials
cisplatin
Resistant
:
C3
cisplatin
Resistant: C3 – Early Trials
cisplatin
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login